PMID- 28188977
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20171204
IS  - 1751-2980 (Electronic)
IS  - 1751-2972 (Linking)
VI  - 18
IP  - 3
DP  - 2017 Mar
TI  - Lack of incremental effect of histamine receptor antagonists over proton pump 
      inhibitors on the risk of neoplastic progression in patients with Barrett's 
      esophagus: a cohort study.
PG  - 143-150
LID - 10.1111/1751-2980.12457 [doi]
AB  - OBJECTIVE: Long-term acid suppression reduces the risk of progression to 
      esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). Given 
      recent reports about the harmful effects of using chronic proton pump inhibitors 
      (PPI) there is renewed interest in alternative methods of acid suppression. 
      Hence, we studied the effect of H2 receptor antagonists (H(2) RA) on the risk of 
      progression to neoplasia in our BE cohort. METHODS: This is a retrospective 
      analysis of prospectively collected data of patients in our BE registry from 2002 
      to 2015. Patients' characteristics, endoscopic findings, such as the length of 
      BE, hiatal hernia size and histological findings and patients' use of medications 
      such as PPI, aspirin, H(2) RA, metformin and antihyperlipidemic agents were 
      studied. RESULTS: The cohort consisted of 1466 patients with a mean age of 61 +/- 
      13 years. The patients had a predominance of male sex (76.7% [1118/1457]) and 
      Caucasian race (96.6% [1209/1252]). After excluding prevalent high-grade 
      dysplasia (HGD) or EAC, 1025 patients had a median follow up of 43.6 months 
      during which 57 patients progressed to HGD or EAC. PPI use (56% in progressors vs 
      69% in non-progressors; P = 0.007) but not H(2) RA use (12% progressors vs 19% in 
      non-progressors P = 0.162) was associated with lower risk of neoplastic 
      progression. On multivariate analysis, there was no synergistic effect of 
      addition of H(2) RA to PPI on risk of neoplastic progression to HGD or EAC 
      (relative risk 0.33; confidence intervals 0.05-2.29, P = 0.262). CONCLUSION: H(2) 
      RA do not seem to have a chemopreventive role in patients with BE.
CI  - (c) 2017 Chinese Medical Association Shanghai Branch, Chinese Society of 
      Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University 
      School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Thota, Prashanthi N
AU  - Thota PN
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, 
      USA.
FAU - Hajifathalian, Kaveh
AU  - Hajifathalian K
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Benjamin, Tanmayee
AU  - Benjamin T
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, 
      USA.
FAU - Runkana, Ashok
AU  - Runkana A
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, 
      USA.
FAU - Lopez, Rocio
AU  - Lopez R
AD  - Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, 
      USA.
FAU - Sanaka, Madhusudhan R
AU  - Sanaka MR
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, 
      USA.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Dig Dis
JT  - Journal of digestive diseases
JID - 101302699
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/epidemiology/pathology/*prevention & control
MH  - Adult
MH  - Aged
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Barrett Esophagus/epidemiology/*pathology
MH  - Disease Progression
MH  - Esophageal Neoplasms/epidemiology/pathology/*prevention & control
MH  - Esophagoscopy
MH  - Female
MH  - Follow-Up Studies
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ohio/epidemiology
MH  - Precancerous Conditions/epidemiology/*pathology
MH  - Prevalence
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Assessment/methods
OTO - NOTNLM
OT  - Barrett's esophagus
OT  - antagonist
OT  - dysplasia
OT  - histamine receptor
OT  - neoplasia
OT  - progression
EDAT- 2017/02/12 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/02/12 06:00
PHST- 2016/11/15 00:00 [received]
PHST- 2017/02/04 00:00 [revised]
PHST- 2017/02/05 00:00 [accepted]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/02/12 06:00 [entrez]
AID - 10.1111/1751-2980.12457 [doi]
PST - ppublish
SO  - J Dig Dis. 2017 Mar;18(3):143-150. doi: 10.1111/1751-2980.12457.